AbbVie reports positive long-term results for atogepant in migraine prevention
AbbVie Inc. (NYSE: ABBV) has announced encouraging findings from an interim analysis of a 156-week extension study, assessing the long-term safety and effectiveness of atogepant, ... Read More
Eli Lilly’s Emgality gets FDA green light for migraine prevention
Eli Lilly and Company has secured approval from the US Food and Drug Administration (FDA) for its migraine drug Emgality (galcanezumab-gnlm) as a preventative therapy ... Read More
Teva secures FDA approval for Ajovy injection in migraine prevention
Teva Pharmaceutical Industries has achieved a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) approving Ajovy (fremanezumab-vfrm) injection for migraine prevention in ... Read More